COVID-19 “Rebound” Linked With Nirmatrelvir/Ritonavir, New Study

September 5, 2022 Maritime Safety News

A recent study shows rapid relapse of coronavirus disease 2019 (COVID-19) symptoms following the administration of nirmatrelvir/ritonavir in adults, reports News Medical.

Nirmatrelvir inhibits the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and blocks viral replication. The antiviral drug markedly lowers disease severity in at-risk individuals.

The study and findings

The present study observed the relapse of COVID-19 symptoms and viral load after an early…


CREWEXPRESS STCW REST HOURS SOFTWARE - Paris and Tokyo MoU have announced that they will jointly launch a new Concentrated Inspection Campaign (CIC) on Standards of Training, Certification and Watchkeeping for Seafarers (STCW) from 1st September 2022 to 30th November 2022